How to buy Tyra Biosciences stock (Tyra Biosciences)

Tyra Biosciences is a biotechnology business based in the US. Tyra Biosciences shares (TYRA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $14.00 – a decrease of 6.29% over the previous week. Tyra Biosciences employs 49 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Tyra Biosciences stock

Buy Tyra Biosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Tyra Biosciences stock price (NASDAQ: TYRA)

Use our graph to track the performance of TYRA stocks over time.

Tyra Biosciences shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$14.00
52-week range	$11.24 - $29.60
50-day moving average more info button	$18.48
200-day moving average more info button	$18.90
Wall St. target price	$31.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.61

Is it a good time to buy Tyra Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tyra Biosciences price performance over time

Historical closes compared with the close of $14 from 2024-12-20

1 week (2024-12-13)	-6.29%
1 month (2024-11-22)	-11.56%
3 months (2024-09-20)	-42.53%
6 months (2024-06-21)	-17.98%

1 year (2023-12-22)	4.09%
2 years (2022-12-22)	59.45%
3 years (2021-12-22)	14.23
5 years (2019-12-18)	N/A

Tyra Biosciences financials

Gross profit TTM	$0
Return on assets TTM	-20.21%
Return on equity TTM	-28.66%
Profit margin	0%
Book value	$6.85
Market Capitalization more info button	$734.8 million

TTM: trailing 12 months

Tyra Biosciences share dividends

We're not expecting Tyra Biosciences to pay a dividend over the next 12 months.

You may also wish to consider:

Tyra Biosciences share price volatility

Over the last 12 months, Tyra Biosciences's shares have ranged in value from as little as $11.24 up to $29.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tyra Biosciences's is 1.078. This would suggest that Tyra Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

To put Tyra Biosciences's beta into context you can compare it against those of similar companies.

• BioNTech (BNTX.US): 0.259
• Harpoon Therapeutics (HARP.US): 2.098
• Aptevo Therapeutics (APVO.US): 5.066

Tyra Biosciences overview

Tyra Biosciences, Inc. , a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. .

Frequently asked questions

What percentage of Tyra Biosciences is owned by insiders or institutions?
Currently 4.776% of Tyra Biosciences shares are held by insiders and 95.82% by institutions. How many people work for Tyra Biosciences?
Latest data suggests 49 work at Tyra Biosciences. When does the fiscal year end for Tyra Biosciences?
Tyra Biosciences's fiscal year ends in December. Where is Tyra Biosciences based?
Tyra Biosciences's address is: 2656 State Street, Carlsbad, CA, United States, 92008 What is Tyra Biosciences's ISIN number?
Tyra Biosciences's international securities identification number is: US90240B1061